77
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Adverse drug reaction and causality assessment scales

      letter
      Lung India : Official Organ of Indian Chest Society
      Medknow Publications

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Sir, I read with interest the articles by Gupta et al and Gulati et al on adverse drug reactions of antituberculous drugs.[1 2] I would like to make the following comments. Adverse drug reactions (ADRs) are a major cause of morbidity, hospital admission, and even death. Hence it is essential to recognise ADRs and to establish a causal relationship between the drug and the adverse event. It is desirable that ADRs should be objectively assessed and presented based on an acceptable “Probability Scale.” Many causality methods have been proposed to assess the relationship between a drug and an adverse event in a given patient, ranging from short questionnaires to comprehensive algorithms. The idea of creating a standardized assessment for the relationship-likelihood of case reports of suspected ADRs was in the hope that this would, in a structured way, lead to a reliable reproducible measurement of causality. The causality assessment system proposed by the World Health Organization Collaborating Centre for International Drug Monitoring, the Uppsala Monitoring Centre (WHO–UMC), and the Naranjo Probability Scale are the generally accepted and most widely used methods for causality assessment in clinical practice as they offer a simple methodology.[3 4] The above scales are structured, transparent, consistent, and easy to apply assessment methods. Table 1 summarizes the “Naranjo ADR Probability Scale,” which has gained popularity among clinicians because of its simplicity.[3] The WHO–UMC causality system takes into account the clinical-pharmacologic aspects, whereas previous knowledge of the ADR plays a less prominent role. Table 2 summarizes the WHO–UMC Probability Scale.[4] Table 1 Naranjo ADR probability scale—items and score Question Yes No Don’t know Are there previous conclusion reports on this reaction? +1 0 0 Did the adverse event appear after the suspect drug was administered? +2 –1 0 Did the AR improve when the drug was discontinued or a specific antagonist was administered? +1 0 0 Did the AR reappear when drug was re-administered? +2 –1 0 Are there alternate causes [other than the drug] that could solely have caused the reaction? –1 +2 0 Did the reaction reappear when a placebo was given? –1 +1 0 Was the drug detected in the blood [or other fluids] in a concentration known to be toxic? +1 0 0 Was the reaction more severe when the dose was increased or less severe when the dose was decreased? +1 0 0 Did the patient have a similar reaction to the same or similar drugs in any previous exposure? +1 0 0 Was the adverse event confirmed by objective evidence? +1 0 0 Scoring for Naranjo algorithm: >9 = definite ADR; 5–8 = probable ADR; 1–4 = possible ADR; 0 = doubtful ADR. Table 2 WHO–UMC causality categories Causality term Assessment criteria (all points should be reasonably complied) Certain Event or laboratory test abnormality, with plausible time relationship to drug intake Cannot be explained by disease or other drugs Response to withdrawal plausible (pharmacologically, pathologically) Event definitive pharmacologically or phenomenologically (ie, an objective and specific medical disorder or a recognized pharmacologic phenomenon) Rechallenge satisfactory, if necessary Probable/likely Event or laboratory test abnormality, with reasonable time relationship to drug intake Unlikely to be attributed to disease or other drugs Response to withdrawal clinically reasonable Rechallenge not required Possible Event or laboratory test abnormality, with reasonable time relationship to drug intake Could also be explained by disease or other drugs Information on drug withdrawal may be lacking or unclear Unlikely Event or laboratory test abnormality, with a time to drug intake that makes a relationship improbable (but not impossible) Disease or other drugs provide plausible explanation Conditional/unclassified Event or laboratory test abnormality More data for proper assessment needed, or Additional data under examination Unassessable/unclassifiable Report suggesting an adverse reaction Cannot be judged because information is insufficient or contradictory Data cannot be supplemented or verified I humbly request the Editors that Lung India should use either of the above two scales while reviewing articles related to ADRs.

          Related collections

          Most cited references3

          • Record: found
          • Abstract: not found
          • Article: not found

          Isoniazid-induced alopecia

            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Erythema multiforme due to antitubercular drugs

            Sir, An 84-year-old male, resident of Delhi, India presented to our hospital with complaints of maculopapular rashes in bilateral extremities since 2 days. There was no orogenital involvement. Rashes did not involve the trunk or abdomen and were also not associated with itching. There was history of starting category I antitubercular therapy, comprising of rifampicin, isoniazid, ethambutol, and pyrazinamide, two months prior to present admission for pulmonary tuberculosis. Patient was not taking any other drugs, besides antitubercular drugs. Apart from the maculopapular rashes in the extremities [Figure 1] there were no significant general or systemic examination findings. The hematological parameters revealed eosinophilia with an absolute eosinophil count of 1890/cu mm. Other biochemical parameters, including liver function tests (total bilirubin: 0.6 mg/dl, direct bilirubin: 0.1 mg/dl, serum alkaline phosphatase: 74 IU/l, serum aspartate aminotransferase: 19 IU/l, serum alanine aminotransferase: 20 IU/l) were normal. ANA and HIV Elisa were also negative. The chest X-ray done on the day of admission showed resolution as compared to previous X-rays. Skin biopsy was suggestive of erythema multiforme[Figure 2]. All the antitubercular drugs were discontinued simultaneously, and the lesions improved gradually. Skin lesions were treated conservatively with oral antihistaminics. After the lesions improved, individual antitubercular drugs were reintroduced one-by-one. The doses of the drugs were increased gradually until the maximum dose was achieved. The offending drug is usually identified during the course of this rechallenge. The drug which causes repeat skin lesions is discontinued immediately and is not given to patient again. In our patient, we could successfully reintroduce rifampicin, isoniazid, and ethambutol without any untoward skin reactions. Pyrazinamide was not given as patient had already completed 2 months of antitubercular therapy with improvement in chest X-ray. Thus, we can indirectly conclude that probably pyrazinamide was the offending drug. Figure 1 Clinical photograph showing maculopapular rashes over extremeties Figure 2 Light microscopy showing an inflammatory infilterate, keratinocyte necrosis in epidermis and dermal eosinophils Skin involvement in tuberculosis can be due to tuberculosis itself or due to the antitubercular drugs. A tuberculous chancre, erythema nodosum, scrofuloderma, lupus vulgaris, tuberculosis verrucosa cutis or a tubercular gumma are various types of cutaneous tuberculosis. Other than this, tuberculids are skin reactions that exhibit tuberculoid features histologically but do not contain detectable mycobacteria. Papulonecrotic and lichen scrofulosorum are the two types of tuberculids. Erythema multiforme (EM) is a relatively common, acute, often recurrent inflammatory disease. Many factors have been implicated in the etiology of EM, including numerous infectious agents, drugs, physical agents, X-ray therapy, pregnancy, and internal malignancies. The drugs implicated in etiology of EM are Sulfonamides including hypoglycemics, nonsteroidal anti-inflammatory drugs (NSAIDs), anticonvulsants, barbiturates, antituberculous drugs, antibiotics, pyrazolones, phenylbutazone, oxyphenbutazone, and phenazone and salicylates. EM is commonly associated with a preceding acute upper respiratory tract infection, herpes simplex infection (HSV), or mycoplasma pneumoniae infection such as primary atypical pneumonia.[1] Studies suggest that immune complex formation and subsequent deposition in the cutaneous microvasculature may play a role in the pathogenesis of EM. A new classification, based on the pattern and distribution of cutaneous lesions, separates erythema multiforme major from Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis.[2–4] Target lesions and papules are the most characteristic eruptions. Dusky red, round maculopapules appear suddenly in a symmetric pattern on the backs of the hands and feet and the extensor aspect of the forearms and legs. The trunk may be involved in more severe cases. The diagnosis may not be suspected until the nonspecific early lesions evolve into target lesions during a 24- to 48-h period. The classic “iris” or target lesion results from centrifugal spread of the red maculopapule to a circumference of 1–3 cm as the center becomes cyanotic, purpuric, or vesicular. The mature target lesion consists of two distinct zones: an inner zone of acute epidermal injury with necrosis or blisters and an outer zone of erythema. There may be a middle zone of pale edema. Mild cases are not treated. Patients with many target lesions respond rapidly to a 1- to 3-week course of prednisone. Oral acyclovir (400 mg twice a day) used continually prevents herpes-associated recurrent EM in many cases. If these treatments fail, dapsone or antimalarial drugs may be tried. Azathioprine was used successfully in patients with severe disease for whom all other treatments had failed.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Erythema multiforme due to antitubercular drugs

                Bookmark

                Author and article information

                Journal
                Lung India
                LI
                Lung India : Official Organ of Indian Chest Society
                Medknow Publications (India )
                0970-2113
                0974-598X
                Apr-Jun 2011
                : 28
                : 2
                : 152-153
                Affiliations
                Department of Pediatrics, Lokmanya Tilak Municipal General Hospital and Medical College, Sion, Mumbai - 400 022, India. E-mail: drzakisyed@ 123456gmail.com
                Article
                LI-28-152
                10.4103/0970-2113.80343
                3109846
                21712934
                d6ce91b3-6866-4db7-91ec-47d1333ff5f1
                © Lung India

                This is an open-access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                Categories
                Letters to Editor

                Respiratory medicine
                Respiratory medicine

                Comments

                Comment on this article